Translating Antisense Technology into a Treatment for Huntington’s Disease
| Autor: | C. Frank Bennett, Tiffany L. Baumann, Holly B. Kordasiewicz, Marc Gleichmann, Anne Smith, Daniel A. Norris, Roger Lane |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Huntingtin Computational biology Biology medicine.disease 03 medical and health sciences Exon 030104 developmental biology 0302 clinical medicine Huntington's disease Drug development Antisense Technology Huntingtin Protein medicine Gene silencing Trinucleotide repeat expansion 030217 neurology & neurosurgery |
| Zdroj: | Methods in Molecular Biology ISBN: 9781493978243 |
| DOI: | 10.1007/978-1-4939-7825-0_23 |
| Popis: | Advances in molecular biology and genetics have been used to elucidate the fundamental genetic mechanisms underlying central nervous system (CNS) diseases, yet disease-modifying therapies are currently unavailable for most CNS conditions. Antisense oligonucleotides (ASOs) are synthetic single stranded chains of nucleic acids that bind to a specific sequence on ribonucleic acid (RNA) and regulate posttranscriptional gene expression. Decreased gene expression with ASOs might be able to reduce production of the disease-causing protein underlying dominantly inherited neurodegenerative disorders. Huntington's disease (HD), which is caused by a CAG repeat expansion in exon 1 of the huntingtin (HTT) gene and leads to the pathogenic expansion of a polyglutamine (PolyQ ) tract in the N terminus of the huntingtin protein (Htt), is a prime candidate for ASO therapy.State-of-the art translational science techniques can be applied to the development of an ASO targeting HTT RNA, allowing for a data-driven, stepwise progression through the drug development process. A deep and wide-ranging understanding of the basic, preclinical, clinical, and epidemiologic components of drug development will improve the likelihood of success. This includes characterizing the natural history of the disease, including evolution of biomarkers indexing the underlying pathology; using predictive preclinical models to assess the putative gain-of-function of mutant Htt protein and any loss-of-function of the wild-type protein; characterizing toxicokinetic and pharmacodynamic effects of ASOs in predictive animal models; developing sensitive and reliable biomarkers to monitor target engagement and effects on pathology that translate from animal models to patients with HD; establishing a drug delivery method that ensures reliable distribution to relevant CNS tissue; and designing clinical trials that move expeditiously from proof of concept to proof of efficacy. This review focuses on the translational science techniques that allow for efficient and informed development of an ASO for the treatment of HD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|